Hologic, Inc.
HOLX
Classificação em ações
#1327
Hologic, Inc. is a medical technology company focused on designing, producing,... Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
Preço da ação
$76.01
Última sincronização: 2026-04-07
Valor de mercado
$16.97B
Variação (1 dia)
0.00%
Variação (1 ano)
5.76%
País
US
Negociar Hologic, Inc. (HOLX)
Categoria
Healthcare
Rácio P/E de Hologic, Inc. (HOLX)
Rácio P/E em October 2026 TTM: 30.28
De acordo com os últimos relatórios financeiros e o preço das ações da Hologic, Inc., o rácio P/E atual (TTM) é 30.28. No final de 2024, a empresa tinha um P/E de 24.32.
Histórico do rácio P/E da Hologic, Inc. de 2000 a 2026
Rácio P/E no final de cada ano
| Ano | Índice P/E | Alterar |
|---|---|---|
| 2026 (TTM) | 30.28 | 12.20% |
| 2025 | 26.99 | 10.98% |
| 2024 | 24.32 | -35.24% |
| 2023 | 37.56 | 208.68% |
| 2022 | 12.17 | 15.83% |
| 2021 | 10.50 | -30.71% |
| 2020 | 15.16 | -104.56% |
| 2019 | -332.48 | 228.24% |
| 2018 | -101.29 | -845.41% |
| 2017 | 13.59 | -58.28% |
| 2016 | 32.57 | -61.81% |
| 2015 | 85.28 | -78.02% |
| 2014 | 387.93 | -8,197.69% |
| 2013 | -4.79 | -93.36% |
| 2012 | -72.18 | -378.49% |
| 2011 | 25.92 | -137.77% |
| 2010 | -68.63 | 3,475.81% |
| 2009 | -1.92 | -84.96% |
| 2008 | -12.76 | -137.01% |
| 2007 | 34.47 | -53.31% |
| 2006 | 73.81 | 81.19% |
| 2005 | 40.74 | 28.34% |
| 2004 | 31.74 | -65.78% |
| 2003 | 92.76 | -90.85% |
| 2002 | 1.01K | -27,142.68% |
| 2001 | -3.75 | -38.76% |
| 2000 | -6.12 | 0.00% |
Rácio P/E para empresas semelhantes ou concorrentes
| Empresa | Rácio P/E | Diferença do rácio P/E | País |
|---|---|---|---|
| 47.48 | 56.80% |
US
|
|
| 27.43 | -9.43% |
FR
|
|
| - | - |
JP
|
|
| 56.89 | 87.88% |
US
|
|
| - | - |
CH
|
Como interpretar um P/E Ratio?
O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.
Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.
Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.